Clear Search sequence regions


  • CD14 (2)
  • cdna (1)
  • cohort (1)
  • curdlan (4)
  • cytokines (3)
  • dectin 1 (1)
  • graft (1)
  • hemophagocytic lymphohistiocytosis (1)
  • HSC (2)
  • human (2)
  • IL 10 (1)
  • IL 6 (1)
  • ligand (1)
  • MCP 1 (1)
  • monocytes (2)
  • NOD2 (3)
  • patients (4)
  • protein human (1)
  • serum (1)
  • stem cell transplant (1)
  • therapies (1)
  • weight (1)
  • weight loss (1)
  • XIAP (9)
  • xiap protein human (1)
  • Sizes of these terms reflect their relevance to your search.

    X-linked inhibitor of apoptosis protein (XIAP) deficiency is a severe immunodeficiency with clinical features including hemophagocytic lymphohistiocytosis (HLH) and inflammatory bowel disease (IBD) due to defective NOD2 responses. Management includes immunomodulatory therapies and hematopoietic stem cell transplant (HSCT). However, this cohort is particularly susceptible to the chemotherapeutic regimens and acutely affected by graft-vs-host disease (GvHD), driving poor long-term survival in transplanted patients. Autologous HSC gene therapy could offer an alternative treatment option and would abrogate the risks of alloreactivity. Hematopoietic progenitor (Lin-ve) cells from XIAPy/- mice were transduced with a lentiviral vector encoding human XIAP cDNA before transplantation into irradiated XIAP y/- recipients. After 12 weeks animals were challenged with the dectin-1 ligand curdlan and recovery of innate immune function was evaluated though analysis of inflammatory cytokines, body weight, and splenomegaly. XIAP patient-derived CD14+ monocytes were transduced with the same vector and functional recovery was demonstrated using in vitro L18-MDP/NOD2 assays. In treated XIAPy/- mice, ~40% engraftment of gene-corrected Lin-ve cells led to significant recovery of weight loss, splenomegaly, and inflammatory cytokine responses to curdlan, comparable to wild-type mice. Serum IL-6, IL-10, MCP-1, and TNF were significantly reduced 2-h post-curdlan administration in non-corrected XIAPy/- mice compared to wild-type and gene-corrected animals. Appropriate reduction of inflammatory responses was observed in gene-corrected mice, whereas non-corrected mice developed an inflammatory profile 9 days post-curdlan challenge. In gene-corrected patient CD14+ monocytes, TNF responses were restored following NOD2 activation with L18-MDP. Gene correction of HSCs recovers XIAP-dependent immune defects and could offer a treatment option for patients with XIAP deficiency. © 2022. The Author(s).

    Citation

    Joseph Topal, Neelam Panchal, Amairelys Barroeta, Anna Roppelt, Annelotte Mudde, H Bobby Gaspar, Adrian J Thrasher, Benjamin C Houghton, Claire Booth. Lentiviral Gene Transfer Corrects Immune Abnormalities in XIAP Deficiency. Journal of clinical immunology. 2023 Feb;43(2):440-451

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 36329240

    View Full Text